CRISPR Therapeutics heads into the second half of 2026 carrying one of the most charged short-side setups in biotech — short interest has jumped 20% in a single week while the stock trails its gene-editing peers by a meaningful margin.
The short positioning is the clearest story this week. Short interest climbed to roughly 25.8% of the free float, up from around 21.5% a week ago — a move of more than 4 percentage points in five sessions. That puts short interest back near levels last seen in early June, when it briefly spiked above 26% before easing through mid-month. The ORTEX short score reflects this: it climbed to 81.7 on Tuesday, the highest reading in the recent history shown, and has held above 79 every day for the past two weeks. Days to cover from the latest FINRA fortnightly data stands near 16, meaning a meaningful short covering event would take well over three weeks at average trading volumes.
The borrow market, however, does not corroborate the short surge with any squeeze pressure. Availability has actually loosened considerably — from around 36% on June 15, when borrow was genuinely tight, to 93% now. That means for every share currently borrowed, nearly another share is still available in the lending pool. Cost to borrow has ticked up about 15% on the week to 0.88%, but at under 1% annually it remains near the floor for a stock of this short interest profile. The options market sends a similar message: the put/call ratio at 0.54 is actually running slightly below its 20-day average of 0.55, with a z-score of -0.88. Options traders are not hedging aggressively — if anything, the mild call skew suggests the market is leaning more bullish than the short interest build implies. Positioning looks contested rather than resolved.
The Street remains broadly constructive on the name, though the gap between analyst targets and the current price tells most of the story. The consensus is Buy, with 10 buys and 5 outperform ratings and no sell ratings visible in the data. The most recent target changes — from Bernstein and Citigroup in May — both involved raises, lifting targets to $56 and $82 respectively, though the spread between those two figures reflects genuine disagreement about how to value the pipeline. At $54.54, the stock trades below even the more cautious Bernstein target of $56, while bulls at Piper Sandler have a $110 target in place from March. The price-to-book multiple has drifted higher to 3.19x, up about 0.32x over the past month, reflecting a modest re-rating even as the stock is down nearly 3% over the same period. The short score factor rank of 4 out of 100 and a DTC rank of 7 confirm that CRSP sits at the extreme end of its universe on short positioning metrics. EPS momentum scores of 24-27 reinforce that near-term fundamental improvement is not the bull case here — this is a pipeline story.
The divergence with peers is worth noting. Over the past week NTLA gained 11%, RXRX rose 16%, and EDIT climbed 17%, while CRSP managed just 1%. BEAM and SANA were more modest at 3-4%, but even they outpaced CRSP. The relative underperformance comes despite no obvious single-stock negative catalyst — the next earnings event is scheduled for August 3, and the bear case centres on Casgevy's modest commercial uptake and persistent cash burn rather than any fresh news. Insiders have not signalled alarm either; the most recent disclosed trades in May were routine CMO sell-and-award transactions tied to compensation, and the 90-day net insider activity shows a small net positive in shares terms, albeit driven by awards rather than open-market buying.
The August 3 earnings date becomes the focal point: with short interest near a recent high, borrow loose, and peers pulling ahead, the question for the next five weeks is whether the short build reflects a specific catalyst trade around the print, or a broader reassessment of Casgevy's commercial trajectory.
See the live data behind this article on ORTEX.
Open CRSP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
